Home › Companies › Ocular Therapeutix, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Ocular Therapeutix, Inc.’s Form 8-K, filed June 12, 2026 (Item 5.07 on EDGAR). Page generated October 25, 2026.
Meeting of June 10, 2026: 5 items on Ocular Therapeutix, Inc.’s Form 8-K, filed June 12, 2026: 2 elected · 2 approved · 1 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Ocular Therapeutix, Inc. in the interactive database Compare manager voting policies
These tallies are Ocular Therapeutix, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Pravin U. Dugel, M.D. | 142,371,228 | -- | -- | 14,705,114 | 32,446,509 | 91% | Elected | — |
| Elect Director: Merilee Raines | 136,531,519 | -- | -- | 20,544,823 | 32,446,509 | 87% | Elected | — |
| (2) The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the 2026 Proxy Statement. | 116,101,559 | 40,115,637 | 859,146 | -- | 32,446,509 | 74% | Approved | — |
| (3) The Company's stockholders approved, on a non-binding, advisory basis, "One Year" for the frequency of future advisory votes to approve the compensation of the Company's named executive officers. | 150,723,228 | 5,688,862 | 664,252 | -- | 32,446,509 | 96% | Not verified | — |
| (5) The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026. | 187,152,838 | 2,113,944 | 256,069 | -- | -- | 99% | Approved | — |
Source: Ocular Therapeutix, Inc., Form 8-K, filed with the SEC on June 12, 2026 — read the filing on EDGAR.
Each item below shows how the 224 asset managers that disclosed a Ocular Therapeutix, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Ocular Therapeutix, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 5 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: To elect two Class III directors, each to serve until the 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Merilee Raines
Ocular Therapeutix, Inc.’s own tally for this item (“Elect Director: Merilee Raines”): 136,531,519 for, 20,544,823 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “(1) The Company's stockholders elected Pravin U. Dugel, M.D. and Merilee Raines as Class III directors to serve until the 2029 Annual Meeting of Stockholders, each such director to hold office until his or her successor has been duly elected and qualified.”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 49,212,460 for, 4,468,230 withheld, 78,167 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 23,195,749 | 0 | 0 | 23,200 | For |
| Vanguard | 10,200,208 | 0 | 49 | 44,992 | For |
| BlackRock | 6,832,742 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,840,331 | 0 | 0 | 0 | For |
| Charles Schwab | 1,463,250 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 1,165,227 | Withhold |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 894,793 | Withhold |
| Equitable | 255,976 | 0 | 0 | 468,171 | Mixed |
| Dimensional | 0 | 0 | 0 | 401,459 | Withhold |
| TIAA | 384,622 | 0 | 0 | 0 | For |
| Brighthouse | 177,700 | 0 | 0 | 155,373 | Mixed |
| Principal | 0 | 0 | 0 | 326,514 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 306,197 | 0 | 0 | 0 | For |
| Allspring | 0 | 0 | 0 | 303,716 | Withhold |
| OPTIMUM FUND TRUST | 234,547 | 0 | 0 | 0 | For |
| JPMorgan | 204,749 | 0 | 0 | 0 | For |
| Lincoln Financial | 153,778 | 0 | 0 | 0 | For |
| Empower | 119,028 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 0 | 0 | 0 | 110,000 | Withhold |
| Transamerica | 106,100 | 0 | 0 | 0 | For |
| WESMARK FUNDS | 0 | 0 | 0 | 103,000 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 99,175 | Withhold |
| 1290 Funds | 0 | 0 | 0 | 90,230 | Withhold |
| Simplify Exchange Traded Funds | 90,000 | 0 | 0 | 0 | For |
| Global X | 89,038 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.
Combines 6 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: To elect two Class III directors, each to serve until the 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Pravin U. Dugel, M.D.
Ocular Therapeutix, Inc.’s own tally for this item (“Elect Director: Pravin U. Dugel, M.D.”): 142,371,228 for, 14,705,114 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “(1) The Company's stockholders elected Pravin U. Dugel, M.D. and Merilee Raines as Class III directors to serve until the 2029 Annual Meeting of Stockholders, each such director to hold office until his or her successor has been duly elected and qualified.”
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 52,099,529 for, 1,581,175 withheld, 78,153 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 23,195,749 | 0 | 0 | 23,200 | For |
| Vanguard | 10,223,914 | 0 | 35 | 21,300 | For |
| BlackRock | 6,832,742 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,840,331 | 0 | 0 | 0 | For |
| Charles Schwab | 1,463,250 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,165,227 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 894,793 | 0 | 0 | 0 | For |
| Equitable | 724,147 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 401,459 | Withhold |
| TIAA | 384,622 | 0 | 0 | 0 | For |
| Brighthouse | 177,700 | 0 | 0 | 155,373 | Mixed |
| Principal | 313,880 | 0 | 0 | 12,634 | For |
| QUANTITATIVE MASTER SERIES LLC | 306,197 | 0 | 0 | 0 | For |
| Allspring | 0 | 0 | 0 | 303,716 | Withhold |
| OPTIMUM FUND TRUST | 234,547 | 0 | 0 | 0 | For |
| JPMorgan | 204,749 | 0 | 0 | 0 | For |
| Lincoln Financial | 153,778 | 0 | 0 | 0 | For |
| Empower | 119,028 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 0 | 0 | 0 | 110,000 | Withhold |
| Transamerica | 106,100 | 0 | 0 | 0 | For |
| WESMARK FUNDS | 0 | 0 | 0 | 103,000 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 99,175 | Withhold |
| 1290 Funds | 0 | 0 | 0 | 90,230 | Withhold |
| Simplify Exchange Traded Funds | 90,000 | 0 | 0 | 0 | For |
| Global X | 89,038 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.
99.9% of fund votes cast · no official result
Description as filed by funds: TO APPROVE AN AMENDMENT TO THE OCULAR THERAPEUTIX, INC. 2021 STOCK INCENTIVE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE THEREUNDER BY 10,000,000 SHARES.
The 58 asset managers below reported 53,538,623 for, 17,069 against, 93,684 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 23,218,949 | 0 | 0 | 0 | For |
| Vanguard | 10,229,296 | 15,950 | 2 | 0 | For |
| BlackRock | 6,832,742 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,840,331 | 0 | 0 | 0 | For |
| Charles Schwab | 1,463,250 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,165,227 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 894,793 | 0 | 0 | 0 | For |
| Equitable | 724,147 | 0 | 0 | 0 | For |
| Dimensional | 401,459 | 0 | 0 | 0 | For |
| TIAA | 384,622 | 0 | 0 | 0 | For |
| Brighthouse | 239,391 | 0 | 93,682 | 0 | Mixed |
| Principal | 326,514 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 306,197 | 0 | 0 | 0 | For |
| Allspring | 303,716 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 234,547 | 0 | 0 | 0 | For |
| JPMorgan | 204,749 | 0 | 0 | 0 | For |
| Lincoln Financial | 153,778 | 0 | 0 | 0 | For |
| Empower | 119,028 | 0 | 0 | 0 | For |
| Transamerica | 106,100 | 0 | 0 | 0 | For |
| WESMARK FUNDS | 103,000 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 99,175 | 0 | 0 | 0 | For |
| 1290 Funds | 90,230 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 90,000 | 0 | 0 | 0 | For |
| Global X | 89,038 | 0 | 0 | 0 | For |
| Northern Trust | 86,877 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.
Combines 3 wordings of this item as funds reported it.
77% Fund and manager reports combined; may count the same shares twice · no official result
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 23,110,431 | 108,518 | 0 | 0 | For |
| Vanguard | 10,216,094 | 29,154 | 2 | 0 | For |
| BlackRock | 0 | 6,832,742 | 0 | 0 | Against |
| T. Rowe Price | 4,840,331 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 1,463,250 | 0 | 0 | Against |
| AllianceBernstein | 1,165,227 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 894,793 | 0 | 0 | 0 | For |
| Equitable | 490,571 | 233,576 | 0 | 0 | Mixed |
| Dimensional | 0 | 401,459 | 0 | 0 | Against |
| TIAA | 384,622 | 0 | 0 | 0 | For |
| Brighthouse | 177,700 | 61,691 | 93,682 | 0 | Mixed |
| Principal | 313,880 | 12,634 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 306,197 | 0 | 0 | Against |
| Allspring | 0 | 303,716 | 0 | 0 | Against |
| OPTIMUM FUND TRUST | 234,547 | 0 | 0 | 0 | For |
| JPMorgan | 204,749 | 0 | 0 | 0 | For |
| Lincoln Financial | 30,578 | 123,200 | 0 | 0 | Mixed |
| Empower | 119,028 | 0 | 0 | 0 | For |
| Transamerica | 106,100 | 0 | 0 | 0 | For |
| WESMARK FUNDS | 0 | 103,000 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 99,175 | 0 | 0 | Against |
| 1290 Funds | 0 | 90,230 | 0 | 0 | Against |
| Simplify Exchange Traded Funds | 90,000 | 0 | 0 | 0 | For |
| Global X | 0 | 89,038 | 0 | 0 | Against |
| Northern Trust | 0 | 86,877 | 0 | 0 | Against |
Fund voting reports, all 57 managers: 42,419,796 for, 11,135,378 against, 93,684 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 32,261,808 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 14,002,481 | 0 | 0 | 0 | For |
| Venrock Adviser, LLC | 10,346,926 | 0 | 0 | 0 | For |
| T. Rowe Price | 7,021,403 | 0 | 0 | 0 | For |
| BlackRock | 15,158 | 6,084,288 | 0 | 0 | Against |
| Point72 | 0 | 5,455,956 | 0 | 0 | Against |
| Avoro Capital Advisors LLC | 4,681,115 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 4,538,394 | 0 | 0 | 0 | For |
| AllianceBernstein | 3,805,929 | 0 | 0 | 0 | For |
| Logos Global Management LP | 0 | 3,483,288 | 0 | 0 | Against |
| DELTEC ASSET MANAGEMENT LLC | 2,284,868 | 0 | 0 | 0 | For |
| State Street | 6,251 | 2,230,491 | 0 | 0 | Against |
| Charles Schwab | 0 | 1,483,590 | 0 | 0 | Against |
| Vanguard | 1,460,626 | 2,319 | 0 | 0 | For |
| Boxer Capital Management, LLC | 1,150,000 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 949,216 | 0 | 0 | Against |
| Empire Life Investments Inc. | 838,830 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 824,066 | 0 | 0 | Against |
| ACUTA CAPITAL PARTNERS, LLC | 593,976 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 558,380 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 0 | 478,558 | 0 | 0 | Against |
| BNP Paribas Asset Management Holding S.A. | 0 | 441,775 | 0 | 0 | Against |
| HighVista Strategies LLC | 441,258 | 0 | 0 | 0 | For |
| Nuveen | 416,263 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 0 | 383,716 | 0 | 0 | Against |
Institutional-manager reports, all 179 managers: 84,933,165 for, 26,501,419 against, 8,815 abstained, 125 not voted, 47,555 1 year. Showing the 25 largest; see all in the interactive database.
Combines 4 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To approve, on a non-binding, advisory basis, the frequency of future advisory votes to approve named executive officer compensation.
Ocular Therapeutix, Inc.’s own tally for this item (“(3) The Company's stockholders approved, on a non-binding, advisory basis, "One Year" for the frequency of future advisory votes to approve the compensation of the Company's named executive officers.”): 150,723,228 for, 5,688,862 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 3 | 0 | Abstain |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| AllianceBernstein | 0 | 0 | 0 | 0 | -- |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| Dimensional | 0 | 0 | 0 | 0 | -- |
| TIAA | 0 | 0 | 0 | 0 | -- |
| Brighthouse | 232,810 | 0 | 93,682 | 0 | Mixed |
| Principal | 0 | 0 | 0 | 0 | -- |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 0 | -- |
| Allspring | 0 | 0 | 0 | 0 | -- |
| OPTIMUM FUND TRUST | 0 | 0 | 0 | 0 | -- |
| JPMorgan | 0 | 0 | 0 | 0 | -- |
| Lincoln Financial | 0 | 0 | 0 | 0 | -- |
| Empower | 0 | 0 | 0 | 0 | -- |
| Transamerica | 0 | 0 | 0 | 0 | -- |
| WESMARK FUNDS | 0 | 0 | 0 | 0 | -- |
| AIG/SunAmerica | 0 | 0 | 0 | 0 | -- |
| 1290 Funds | 0 | 0 | 0 | 0 | -- |
| Simplify Exchange Traded Funds | 0 | 0 | 0 | 0 | -- |
| Global X | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 57 managers: 232,810 for, 93,685 abstained, 52,864,615 1 year, 457,347 3 year, 397 unknown. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Deep Track Capital, LP | 0 | 0 | 0 | 0 | -- |
| Venrock Adviser, LLC | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Point72 | 0 | 0 | 0 | 0 | -- |
| Avoro Capital Advisors LLC | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| AllianceBernstein | 0 | 0 | 0 | 0 | -- |
| Logos Global Management LP | 0 | 0 | 0 | 0 | -- |
| DELTEC ASSET MANAGEMENT LLC | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| Boxer Capital Management, LLC | 0 | 0 | 0 | 0 | -- |
| Candriam S.C.A. | 0 | 0 | 0 | 0 | -- |
| Empire Life Investments Inc. | 884,297 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| ACUTA CAPITAL PARTNERS, LLC | 0 | 0 | 0 | 0 | -- |
| Aberdeen | 0 | 0 | 0 | 0 | -- |
| MELLON INVESTMENTS Corp | 0 | 0 | 0 | 0 | -- |
| BNP Paribas Asset Management Holding S.A. | 0 | 0 | 0 | 0 | -- |
| HighVista Strategies LLC | 0 | 0 | 0 | 0 | -- |
| Nuveen | 0 | 0 | 0 | 0 | -- |
| Orgel Wealth Management, LLC | 394,696 | 0 | 0 | 0 | For |
Institutional-manager reports, all 178 managers: 1,290,833 for, 47,399 against, 125 not voted, 110,586,768 1 year, 139,986 3 year. Showing the 25 largest; see all in the interactive database.
Combines 3 wordings of this item as funds reported it.
99% Approved · of votes cast
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as Ocular Therapeutix's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Ocular Therapeutix, Inc.’s own tally for this item (“(5) The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 187,152,838 for, 2,113,944 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(5) The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 53,665,166 for, 9 against, 93,682 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 23,218,949 | 0 | 0 | 0 | For |
| Vanguard | 10,245,246 | 3 | 0 | 0 | For |
| BlackRock | 6,832,742 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,840,331 | 0 | 0 | 0 | For |
| Charles Schwab | 1,463,250 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,165,227 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 894,793 | 0 | 0 | 0 | For |
| Equitable | 724,147 | 0 | 0 | 0 | For |
| Dimensional | 401,459 | 0 | 0 | 0 | For |
| TIAA | 384,622 | 0 | 0 | 0 | For |
| Brighthouse | 239,391 | 0 | 93,682 | 0 | Mixed |
| Principal | 326,514 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 306,197 | 0 | 0 | 0 | For |
| Allspring | 303,716 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 234,547 | 0 | 0 | 0 | For |
| JPMorgan | 204,749 | 0 | 0 | 0 | For |
| Lincoln Financial | 153,778 | 0 | 0 | 0 | For |
| Empower | 119,028 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 110,000 | 0 | 0 | 0 | For |
| Transamerica | 106,100 | 0 | 0 | 0 | For |
| WESMARK FUNDS | 103,000 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 99,175 | 0 | 0 | 0 | For |
| 1290 Funds | 90,230 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 90,000 | 0 | 0 | 0 | For |
| Global X | 89,038 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 218,896,915 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 10.61% |
| 2 | Vanguard | 4.68% |
| 3 | BlackRock | 3.12% |
| 4 | T. Rowe Price | 2.21% |
| 5 | Charles Schwab | 0.67% |
| 6 | AllianceBernstein | 0.53% |
| 7 | AB DISCOVERY GROWTH FUND, INC. | 0.41% |
| 8 | Equitable | 0.33% |
| 9 | Dimensional | 0.18% |
| 10 | TIAA | 0.18% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 14.74% |
| 2 | Deep Track Capital, LP | 6.40% |
| 3 | Venrock Adviser, LLC | 4.73% |
| 4 | T. Rowe Price | 3.21% |
| 5 | BlackRock | 2.79% |
| 6 | Point72 | 2.49% |
| 7 | Avoro Capital Advisors LLC | 2.14% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.07% |
| 9 | AllianceBernstein | 1.74% |
| 10 | Logos Global Management LP | 1.59% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 14.92% | 13F |
| Deep Track Capital, LP | 9.53% | 13G |
| BlackRock | 7.37% | 13F |
| Vanguard Group | 5.29% | 13F |
| T. Rowe Price | 2.69% | 13F |
| Point72 | 2.53% | 13F |
| State Street | 2.15% | 13F |
| Geode Capital | 2.07% | 13F |
| Two Sigma | 0.84% | 13F |
| Invesco | 0.70% | 13F |
Percentages above are of 218,896,915 shares outstanding, as reported by Ocular Therapeutix, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Ocular Therapeutix, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.
At Ocular Therapeutix, Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 224 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,720 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Ocular Therapeutix, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve an advisory vote on named executive officer compensation. — the reporting funds and managers cast 77% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.
Ocular Therapeutix, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.